205 related articles for article (PubMed ID: 33533986)
1. Impact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study.
Tuca Rodríguez A; Núñez Viejo M; Maradey P; Canal-Sotelo J; Guardia Mancilla P; Gutiérrez Rivero S; Raja Casillas I; Herrera Abián M; López Bermudo C
Support Care Cancer; 2021 Aug; 29(8):4799-4807. PubMed ID: 33533986
[TBL] [Abstract][Full Text] [Related]
2. Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care.
Rodríguez AT; Viejo MN; Maradey P; Canal-Sotelo J; Mancilla PG; Rivero SG; Casillas IR; Abián MH; Bermudo CL
Future Oncol; 2022 May; 18(14):1717-1731. PubMed ID: 35137627
[TBL] [Abstract][Full Text] [Related]
3. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study.
Villarroel PG; Padró JG; Marquina G; Jáñez NM; González EE; Antón A; Sánchez MB; Cáceres AR; López-López R; Cornejo RE; García PB; Fabregat RM; Fernández BC; Bermudo CL; Camps C
Future Oncol; 2022 Nov; 18(35):3913-3927. PubMed ID: 36537885
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
5. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Masel EK; Landthaler R; Gneist M; Watzke HH
Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.
Husic S; Imamovic S; Matic S; Sukalo A
Med Arch; 2017 Aug; 71(4):246-250. PubMed ID: 28974843
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control.
Chiang YH; Lien CT; Su WH; Yen TY; Chen YJ; Lai YL; Lim KH; Dai KY; Chung HP; Hung CY; Leu YS
BMC Palliat Care; 2024 Jun; 23(1):150. PubMed ID: 38877477
[TBL] [Abstract][Full Text] [Related]
8. Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.
Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
Drugs R D; 2019 Sep; 19(3):247-254. PubMed ID: 31177479
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
[TBL] [Abstract][Full Text] [Related]
10. Current management of breakthrough cancer pain according to physicians from pain units in Spain.
Estévez FV; Alarcón MDL; Mayoral V; de Madariaga M; Margarit C; Duran JA; Martín-Arroyo JMT; Carregal A;
Clin Transl Oncol; 2019 Sep; 21(9):1168-1176. PubMed ID: 30783918
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F
Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474
[TBL] [Abstract][Full Text] [Related]
12. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
Guitart J; Vargas I; De Sanctis V; Ferreras J; Fuentes J; Salazar R; Vázquez JM; Folch J; Moya J; Ribera H; Rodelas F; Tomás A; Arilla M; Coma J; Aberasturi T; Sintes D; Lombán E
Clin Drug Investig; 2013 Sep; 33(9):675-83. PubMed ID: 23881567
[TBL] [Abstract][Full Text] [Related]
14. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
Überall MA; Müller-Schwefe GH
Curr Med Res Opin; 2011 Jul; 27(7):1385-94. PubMed ID: 21561313
[TBL] [Abstract][Full Text] [Related]
15. Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
.
Brant JM; Rodgers BB; Gallagher E; Sundaramurthi T
Clin J Oncol Nurs; 2017 Jun; 21(3 Suppl):71-80. PubMed ID: 28524907
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
[TBL] [Abstract][Full Text] [Related]
17. Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.
Mercadante S; Caraceni A; Masedu F; Scipioni T; Aielli F
Oncologist; 2020 Feb; 25(2):156-160. PubMed ID: 31862860
[TBL] [Abstract][Full Text] [Related]
18. Breakthrough cancer pain: review and calls to action to improve its management.
Camps Herrero C; Batista N; Díaz Fernández N; Escobar Álvarez Y; Gonzalo Gómez A; Isla Casado D; Salud A; Terrasa Pons J; Guillem Porta V
Clin Transl Oncol; 2020 Aug; 22(8):1216-1226. PubMed ID: 32002739
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy.
Ferrero VT; Oset MM; Masferrer JP; Pardo EH; Sorolla EJ; Largo SC;
Clin Transl Oncol; 2019 Dec; 21(12):1707-1711. PubMed ID: 30949931
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
Minkowitz H; Bull J; Brownlow RC; Parikh N; Rauck R
Support Care Cancer; 2016 Jun; 24(6):2669-75. PubMed ID: 26780504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]